Analysts: Tesla Has Upside With Mass Market Presence and 3 More Research Notes to Consider

Tesla (NASDAQ:TSLA): Barclays downgraded Tesla from Overweight to Equal Weight based on fair valuation and believes shares reflect the likelihood the company will become a mass market manufacturer. The analyst raised its price target to $141 from $90 and sees upside to $279 if Tesla becomes a mass market success.

Groupon (NASDAQ:GRPN): Deutsche Bank raised its price target for Groupon shares to $17 from $10 following the company’s second quarter results and kept a Buy rating on the stock. Deutsche feels positively about the company’s ability to re-accelerate growth and expand margins.

Jazz Pharmaceuticals (NASDAQ:JAZZ): Citigroup believes the current valuation of Jazz Pharmaceuticals does not reflect the company’s growth prospects outside of Xyrem and its ability diversify revenue. Citi raised its price target for Jazz shares to $93 from $75 following the company’s second quarter results and has kept a Buy rating on the stock.